261 related articles for article (PubMed ID: 22147457)
1. [IDH1/2 mutations in gliomas].
Nobusawa S; Yokoo H
Brain Nerve; 2011 Dec; 63(12):1378-86. PubMed ID: 22147457
[TBL] [Abstract][Full Text] [Related]
2. Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas.
Hartmann C; Meyer J; Balss J; Capper D; Mueller W; Christians A; Felsberg J; Wolter M; Mawrin C; Wick W; Weller M; Herold-Mende C; Unterberg A; Jeuken JW; Wesseling P; Reifenberger G; von Deimling A
Acta Neuropathol; 2009 Oct; 118(4):469-74. PubMed ID: 19554337
[TBL] [Abstract][Full Text] [Related]
3. Biological Significance of Mutant Isocitrate Dehydrogenase 1 and 2 in Gliomagenesis.
Ohba S; Hirose Y
Neurol Med Chir (Tokyo); 2016; 56(4):170-9. PubMed ID: 26960449
[TBL] [Abstract][Full Text] [Related]
4. Isocitrate dehydrogenase-1 mutations: a fundamentally new understanding of diffuse glioma?
Kloosterhof NK; Bralten LB; Dubbink HJ; French PJ; van den Bent MJ
Lancet Oncol; 2011 Jan; 12(1):83-91. PubMed ID: 20615753
[TBL] [Abstract][Full Text] [Related]
5. Metabolism of glioma and IDH1/IDH2 mutations.
Rossetto M; Ciccarino P; Boisselier B; Labussiere M; Sanson M
Rev Neurol (Paris); 2011 Oct; 167(10):699-703. PubMed ID: 21885076
[TBL] [Abstract][Full Text] [Related]
6. Molecular investigation of isocitrate dehydrogenase gene (IDH) mutations in gliomas: first report of IDH2 mutations in Indian patients.
Das BR; Tangri R; Ahmad F; Roy A; Patole K
Asian Pac J Cancer Prev; 2013; 14(12):7261-4. PubMed ID: 24460285
[TBL] [Abstract][Full Text] [Related]
7. Association Between IDH1 and IDH2 Mutations and Preoperative Seizures in Patients with Low-Grade Versus High-Grade Glioma: A Systematic Review and Meta-Analysis.
Phan K; Ng W; Lu VM; McDonald KL; Fairhall J; Reddy R; Wilson P
World Neurosurg; 2018 Mar; 111():e539-e545. PubMed ID: 29288860
[TBL] [Abstract][Full Text] [Related]
8. Non-canonical IDH1 and IDH2 mutations: a clonal and relevant event in an Italian cohort of gliomas classified according to the 2016 World Health Organization (WHO) criteria.
Visani M; Acquaviva G; Marucci G; Paccapelo A; Mura A; Franceschi E; Grifoni D; Pession A; Tallini G; Brandes AA; de Biase D
J Neurooncol; 2017 Nov; 135(2):245-254. PubMed ID: 28748342
[TBL] [Abstract][Full Text] [Related]
9. Diffuse glioma - Rare homozygous IDH point mutation, is it an oncogenetic mechanism?
Singh A; Gurav M; Dhanavade S; Shetty O; Epari S
Neuropathology; 2017 Dec; 37(6):582-585. PubMed ID: 28782849
[TBL] [Abstract][Full Text] [Related]
10. Isocitrate Dehydrogenase
Murugan AK; Alzahrani AS
Br J Biomed Sci; 2022; 79():10208. PubMed ID: 35996504
[No Abstract] [Full Text] [Related]
11. IDH1 and IDH2 mutations in gliomas.
Yan H; Parsons DW; Jin G; McLendon R; Rasheed BA; Yuan W; Kos I; Batinic-Haberle I; Jones S; Riggins GJ; Friedman H; Friedman A; Reardon D; Herndon J; Kinzler KW; Velculescu VE; Vogelstein B; Bigner DD
N Engl J Med; 2009 Feb; 360(8):765-73. PubMed ID: 19228619
[TBL] [Abstract][Full Text] [Related]
12. Clinico-neuropathological features of isocitrate dehydrogenase 2 gene mutations in lower-grade gliomas.
Wang LM; Li Z; Piao YS; Cai YN; Zhang LY; Ge HJ; Xu WW; Lu DH
Chin Med J (Engl); 2019 Dec; 132(24):2920-2926. PubMed ID: 31833906
[TBL] [Abstract][Full Text] [Related]
13. Estimation of the occurrence rates of
Cho U; Yang SH; Yoo C
J Int Med Res; 2021 Jun; 49(6):3000605211019258. PubMed ID: 34162262
[TBL] [Abstract][Full Text] [Related]
14. Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas.
Hartmann C; Hentschel B; Wick W; Capper D; Felsberg J; Simon M; Westphal M; Schackert G; Meyermann R; Pietsch T; Reifenberger G; Weller M; Loeffler M; von Deimling A
Acta Neuropathol; 2010 Dec; 120(6):707-18. PubMed ID: 21088844
[TBL] [Abstract][Full Text] [Related]
15. Isocitrate dehydrogenase mutations: a challenge to traditional views on the genesis and malignant progression of gliomas.
Weller M; Wick W; von Deimling A
Glia; 2011 Aug; 59(8):1200-4. PubMed ID: 21294161
[TBL] [Abstract][Full Text] [Related]
16. Isocitrate dehydrogenase mutation as a therapeutic target in gliomas.
Han CH; Batchelor TT
Chin Clin Oncol; 2017 Jun; 6(3):33. PubMed ID: 28705010
[TBL] [Abstract][Full Text] [Related]
17. Isocitrate dehydrogenase mutations in gliomas.
Waitkus MS; Diplas BH; Yan H
Neuro Oncol; 2016 Jan; 18(1):16-26. PubMed ID: 26188014
[TBL] [Abstract][Full Text] [Related]
18. Anatomical localization of isocitrate dehydrogenase 1 mutation: a voxel-based radiographic study of 146 low-grade gliomas.
Wang Y; Zhang T; Li S; Fan X; Ma J; Wang L; Jiang T
Eur J Neurol; 2015 Feb; 22(2):348-54. PubMed ID: 25318355
[TBL] [Abstract][Full Text] [Related]
19. Distinct IDH1/IDH2 mutation profiles in purely insular versus paralimbic WHO Grade II gliomas.
Gozé C; Mansour L; Rigau V; Duffau H
J Neurosurg; 2013 Apr; 118(4):866-72. PubMed ID: 23330999
[TBL] [Abstract][Full Text] [Related]
20. IDH mutations occur frequently in Chinese glioma patients and predict longer survival but not response to concomitant chemoradiotherapy in anaplastic gliomas.
Qi ST; Yu L; Lu YT; Ou YH; Li ZY; Wu LX; Yao F
Oncol Rep; 2011 Dec; 26(6):1479-85. PubMed ID: 21874255
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]